Chronic vaccination with a therapeutic egf-based cancer vaccine: A review of patients receiving long lasting treatment

Current Cancer Drug Targets

Volumn 11, Issue 1, 2011, Pages 103-110

  Gonzalez, G ^a   Crombet, T ^a   Lage, A ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Cancer vaccines; chronic vaccination; EGF; EGFR

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CANCER VACCINE; CARRIER PROTEIN; CYCLOPHOSPHAMIDE; MONTANIDE ISA 51; RECOMBINANT EPIDERMAL GROWTH FACTOR; RECOMBINANT EPIDERMAL GROWTH FACTOR CARRIER PROTEIN CONJUGATE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); HUMAN; LUNG CANCER; NEISSERIA MENINGITIDIS;

ANIMALS; ANTIBODIES; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; EPIDERMAL GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; VACCINATION;

EID: 78951471862     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911793743583     Document Type: Article

References (49)

1. Dalgleish, A. G.; Whelan, M. A. Cancer vaccines as a therapeutical modality: the long trek. Cancer Immunol. Immunother. 2006, 55, 1025-1032.
2. Scholm, J.; Arlen, P. A.; Gulley, J. L. Cancer vaccines: moving beyond current paradigms. Clin. Cancer Res. 2007, 13, 3776-3782.
3. Lage, A.; Perez, R.; Fernandez, L. E. Therapeutic cancer vaccines: at midway between immunology and pharmacology. Curr. Cancer Drug Targets 2005, 5, 611-627.
4. Pharmaceutical Research and Manufacturing of America.Biotechnology Medicines in Development 2008.www.phrma.org/www.innovation.org/www.pparx.org/www.buysafedrugs.info/www.sharingmiracles.com
5. Dubb, G. P.; Old, LL. J.; Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21, 137-148.
6. Uno, T.; Takeda, K.; Kojima, Y.; Yoshizawa, H.; Akiba, H.; Mittler, R. S.; Gejyo, F.; Okumura, K.; Yaggita, H.; Smyth, M. J. Eradication of stablished tumors in mice by a combination antibody-based therapy. Nat. Med. 2006, 12, 693-698.
7. Boon, T.; Coulie, P. G.; Van den Eunde, B. J.; Van den Bruggen, P. Human T cell responses against melanoma. Annual Rev. Immunol. 2006, 24, 175-208.
8. Rosenberg, S. A.; Yang, J. C.; Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004, 10, 909-915.
9. Finke, L. H.; Wentworth, K.; Blumenstein, B.; Rudolph, N. S.; Levitsky, H.; Hoss, A. Lessons from randomized phase III studies with active cancer immunotherapies. Outcomes from the 2006 meeting of the cancer vaccine consortium (CVC). Vaccine 2007, 25S, B97-B109.
10. Baldwin, R. W. Immunity to methylcholantrene-induced tumors in inbread rats following atrophy and regression of the implanted tumors. Br. J. Cancer 1955, 9, 652-657.
11. Baldwin, R. W.; Price, M. R. Tumor antigens and tumor-host relationships. Ann. Rev. Med. 1976, 27, 151-163.
12. Higano, C. S.; Samll, E. J.; Schellhammer, P.; Yasothan, U.; Gubernik, S.; Kirpatrick, P.; Kantoff, P. W. Sipuleucel-T. Nat. Rev. Drug Discov. 2010, 9, 513-514.
13. Zhou, G.; Drake, Ch. G.; Levitsky, H. I. Amplification of tumor specific regulatory T cells following therapeutic cancer vaccines. Blood 2006, 107, 628-636.
14. Eggermont, A. M. M. Therapeutic vaccines in solid tumors: Can they be harmful? Eur. J. Cancer 2009, 45, 2087-2090.
15. Lee, K. H.; Wang, E.; Nielsen, M. B.; Wunderlich, J.; Migueles, S.; Connors, M.; Steinberg, S. M.; Rosenberg, S. A.; Marincola, F. M. Increased vaccine-specific T cell frequency alter peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 1999, 163, 6292-6300.
16. Callan, M. F. C; Tan, L.; Annels, N.; Ogg, G. S.; Wilson, J. D. K.; ÓCallaghan, C. C.; Steven, N.; McMichael, A. J.; Rickinson, A. B. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to epstein -barr virus in vivo. J. Exp. Med. 1998, 187, 1395-1402.
17. Pinna, D.; Corti, D.; Jarrossay, D.; Sallusto, F.; Lanzavecchia, A. Clonal dissection of human memory B-cell repertoire following infection and vaccination. Eur. J. Immunol. 2009, 39, 1260-1270.
18. Welsh, R. M.; McNally, J. M. Immune deficiency, immune silencing and clonal exhaustion of T cell responses during viral infections. Curr. Opin. Microbiol. 1999, 2, 382-387.
19. Pawelec, G.; Koch, S.; Griesemann, H.; Rehbein, A.; Hahnel, K.; Gouttefangeas, C. Immunosenescence, suppression and tumor progression. Cancer Immunol. Immunother. 2006, 55, 981-986.
20. Badovinac V. P.; Porter, B. B.; Harty, J. T. Programmed contraction of CD8 T cells after infection. Nat. Immunol. 2002, 3, 619-626.
21. González, G.; Crombet, T.; Catalá, M.; Mirabal, V.; Hernández, J. C.; González, Y.; Marinello, P.; Guillén, G.; Lage, A. A novel vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann. Oncol. 1998, 9, 431-435.
22. González, G.; Crombet, T.; Torres, F.; Catalá, M.; Alfonso, L.; Osorio, M.; Neninger, E.; García, B.; Mulet, A.; Pérez, R.; Lage, A. Epidermal growth factor-based cancer vaccine for non-small cell lung cancer therapy. Ann. Oncol. 2003, 14, 461-466.
23. Crombet, T.; Neninger, E.; Catalá, M.; García, B.; Leonard, I.; Martínez, L.; González, G.; Pérez, R.; Lage, A. Treatment of NSCLC patients with an EGF-based cancer vaccibe. Report of a phase I trial. Cancer Biol. Ther. 2006, 5, 145-159.
24. González, G.; Crombet, T.; Neninger, E.; Viada, C.; Lage, A. The rapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer. Analysis of pooled data from three clinical trials. Hum. Vacciene 2007, 3, 8-13.
25. González, G.; Lage, A. Cancer vaccines for hormone/growth factor immune deprivation: a feasible approach for cancer treatment. Curr. Cancer Drug Targets 2007, 7, 191-201.
26. Neninger, E.; de la Torre, A.; Osorio, M.; Catalá, M.; Bravo, I.; Mendoza, M. Abreu, D.; Acosta, S.; Rives, R.; del Castillo, C.; González, M.; Viada, C.; García, B.; Crombet, T.; González, G.; Lage, A. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cal-lung cancer. J. Clin. Oncol. 2008, 26, 1452-1458.
27. García, B.; Neninger, E.; de la Torre, A.; Leonard, I.; Martínez, R.; Viada, C.; González, G.; Mazorra, Z.; Lage, A.; Crombet, T. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin. Cancer Res. 2008, 14, 840-846.
28. Neninger, E.; García, B.; Crombet, T.; Viada, C.; Pereda, S.; Leonard, I.; Mazorra, Z.; Fleites, G.; González, M.; Wilkinson, B.; González, G.; Lage, A. Combining an EGF-based Cancer vaccine with Chemotherapy in advanced Non Small Cell Lung cancer. J. Immunol. 2009, 32, 92-99.
29. Rodríguez P. C.; Rodríguez, G.; González, G.; Lage, A. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small cell lung cancer therapy. MEDDIC Rev. 2010, 12, 17-23.
30. González, G.; Sánchez, B.; Suárez, E.; Beausoleil, I.; Pérez, R.; Lastre, M.; Lage, A. Induction of immune recognition of self epidermal growth factor (EGF): effect on EGF-biodistribution and tumor growth. Vaccine Res. 1996, 5, 233-244
31. González, G.; Pardo, O. L.; Sánchez, B.; García, J. L.; Beausoleil, I.; Marinello, P.; González, Y.; Domarco, A.; Guillén, G.; Pérez, R.; Lage, A. Induction of immune recognition of self-epidermal growth factor II: characterization of the antibody response and use of a fusion protein. Vaccine Res. 1997, 6, 91-100.
32. Guillén, G.; Silva, R.; Alvarez, A.; Coizeau, E.; Novoa, L.; Selman, M.; Morales, J.; Musacchio, A.; del Valle, J.; Delgado, M.; Tamayo, B.; Caballero, E.; Fernandez, J. R.; Herrera, L. In: Cloning and expression of a high molecular weight protein (PM-6) from the Neisseria meningitidis strain B:4P1-15. Evaluation if the immune genicity and bactericidal activity of antibodies raised agiainst the recombinant protein. Conde, C. J. Ed; Pathology and Immunobiology of Neisseriaceae. Mexico City: INSP, 1994, 834-840.
33. Silva, R.; Selman, R.; Guillén, G.; Herrera, L.; Fernandez, J.R.; Novoa, Ll.; Morales, J.; Moreira, V.; González, S.; Tamargo, B.; del Valle, J. A.; Caballero, E.; Alvarez, A.; Coizeau, E.; Cruz, S.; Musacchio, A. Nucleotide sequence coding for an outer mem brande protein from Neisseria meningitidis and use of said sequence in vaccine preparations. USA patent, 5, 286,484, 1994.
34. Rodríguez, G.; Albisa, A.; Viña, L.; Cuevas, A.; García, B.; García, A. T.; Portillo, A.; Calvo, L.; Crombet, T.; González, G.; Chico, E. Manufacturing process development for an epidermal growth factor-based cancer vaccine. Int. Biopharm. 2008, 21, 2-8.
35. th ed. Homewood, IL: Irwin 1996.
36. Nicholsonm, R. I.; Gee, J. M.; Harper, M. E. EGFR and cancer prognosis. Eur. J. Cancer 2003, 41, 5175-5186.
37. Rusch, V.; Baselga, J.; Cordon-Cardo, C.; Orazem, J.; Zaman, M.; McIntosh, J.; Kurie, J.; Dmitrovsky, E. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993, 53, 2379-2385.
38. Rusch, V.; Klimstra, D.; Venkatraman, D.; Pisters, P. W.; Langenfeld, J.; Dmitrovsky, E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. 1997, 3, 515-522.
39. Herzenberg, L. Epitope-specific regulation: the elephant in the bathtub. Nat. Immunol. 2007, 8, 783-786.
40. Llopiz, D.; Dotor, J.; Zabaleta, A.; Lasarte, J. J.; Proeto, J.; Borráscuesta, F.; Sarobe, P. Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effect. Cancer Immunol. Immunother. 2008, 57, 19-29.
41. Crotty, S.; Felgnerm P.; Davies, H.; Glidewell, J.; Villareal, L.; Ahmed, R. Cutting Edge: Long-term B cell memory in humans after smallpox vaccination. J. Immunol. 2003, 171, 4969-4073.
42. Amanna, I. J.; Carlson, N. E.; Slifka, M. K. Duration of the humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 2007, 357, 1903-1915.
43. Fraser, C.; Tomassini, J. E.; Xi, L.; Golm, G.; Watson, M.; Giuliano, A. R.; Barr, E.; Ault, K. A. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 2007, 25, 4324-4333.
44. Atanackovic, D.; Altorki, N. K.; Cao, Y.; Ritter, E.; Ferrara, C. A.; Ritter, G.; Hoffman, E. W.; Bokemeyer, C.; Old, L. J.; Gnajatic, S. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc. Nat. Acad. Sci. USA 2008, 105, 1650-1655.
45. Powell, D. J. Jr.; Rosenberg, S. A. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. J. Immunother. 2004, 27, 36-47.
46. Appay, V.; Jandus, C.; Voelter, V.; Reynard, S.; Coupland, S. E.; Rimoldi, D.; Lienard, D.; Guillaume, P.; Krieg, A. M.; Cerottini, J. C.; Romero, P.; Leyvraz, S.; Rufer, N.; Speiser, D. E. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J. Immunol. 2006, 177, 1670-1678.
47. Speiser, D. E.; Baumgaertner, P.; Barbey, C.; Rubio-Godoy, V.; Moulin, A.; Corthesy, P.; Devevre, E.; Dietrich, P.Y.; Rimoldu, D.; Liénard, D.; Cerottini, J. C.; Romero, P.; Rufer, N. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J. Immunol. 2006, 177, 1338-1348.
48. Hansson, L.; Addalia, A. O.; Moshfegh, A.; Choudhury, A.; Rabbani, H.; Nilsson, B.; Osterborg, A.; Mellsted, H. Long-term idiotype vaccination combined with interleukin 12 (IL12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin. Cancer Res. 2007, 13, 1503-1510.
49. Wherry, E. J.; Ha, S. J.; Kaech, S. M.; Haining, W. N.; Sarkar, S.; Kalia, V.; Subramaniam, S.; Blattman, J. N.; Barber, D. L.; Ahmed, R. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007, 27, 670-684.